Anuh Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹185 Cr −0.5% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
AP

Anuh Pharma Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Anuh Pharma Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹194Cr
+4.3% YoY
−4% QoQ
Net profit
₹11Cr
+37.5% YoY
−8.3% QoQ
Margin
8%
+2 pp YoY
−2 pp QoQ

Anuh Pharma Ltd Q1 FY27 key numbers

Revenue
Operating Profit: Rs. 38.15 Cr, up 39.50% YoY.

As stated in Anuh Pharma Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Anuh Pharma Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹91
Market cap₹937 Cr
P/E21.2

The short version

Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8). EBITDA for Q1 FY27: Rs. 19.36 Cr, a 41.56% increase YoY; EBITDA margin: 9.99% vs. 7.34% in Q1 FY26.

From Anuh Pharma Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8).
  • Production Volume: 491 MT, up 19.46% YoY from 411 MT in Q1 FY26 (Page 6).
  • Operating Profit: Rs. 38.15 Cr, up 39.50% YoY (Page 8).
  • Revenue by Product Groups and Customers: Detailed product-wise revenues and customer concentration referenced but specific figures focus on totals only for Q1 FY27 vs Q1 FY26 (Pages 10-13).

2 more points from Anuh Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Future Outlook (Page 28) mentions "continued investments in compliance, operational efficiency and capacity enhancement."
  • Growth strategy includes "extensive volume expansions across API lines."
  • Infrastructure section highlights existing facilities: Tarapur manufacturing complex (11,400 sq. m) with 9 API blocks and 2 intermediate blocks; 10,000 sq. ft. R&D facility at Mahape, Navi Mumbai, DSIR approved.

2 more points from Anuh Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anuh Pharma Ltd Q1 FY27 results — key figures

Anuh Pharma Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue194186+4.3%202-4%
Operating profit (EBITDA)1610+60%20-20%
Operating margin8%6%+2 pp10%-2 pp
Profit before tax1711+54.5%16+6.3%
Net profit (PAT)118+37.5%12-8.3%
EPS (₹)1.140.83+37.3%1.17-2.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anuh Pharma Ltd Q1 FY27 results?

Q1 FY27 Operating Revenue: Rs. 193.81 Cr, up 3.93% YoY from Rs. 186.48 Cr in Q1 FY26 (Page 6, 8). EBITDA for Q1 FY27: Rs. 19.36 Cr, a 41.56% increase YoY; EBITDA margin: 9.99% vs. 7.34% in Q1 FY26.

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anuh Pharma Ltd planning capital expenditure?

- Future Outlook (Page 28) mentions "continued investments in compliance, operational efficiency and capacity enhancement." - Growth strategy includes "extensive volume expansions across API lines." - Infrastructure section highlights existing facilities: Tarapur manufacturing complex (11,400 sq.

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.